Capital Fund Management (CFM)
VKTX icon

Capital Fund Management (CFM)’s Viking Therapeutics VKTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,300
Closed -$514K – 2526
2025
Q1 		$514K Buy
21,300
+3,800
+22% +$120K ﹤0.01% 1832
2024
Q4 		$704K Buy
+17,500
New +$998K ﹤0.01% 1840

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital Fund Management (CFM)'s VKTX Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Viking Therapeutics (VKTX) stake by 78% in Q1 2026, buying an estimated $292K and bringing the position to 20,824 shares worth $678K. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

Capital Fund Management (CFM) first reported a position in VKTX in Q4 2019 and has held it in 8 quarters since. The position peaked at $4.92M in Q4 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Capital Fund Management (CFM) held 20,824 shares of Viking Therapeutics worth $678K as of Q1 2026.
  • Capital Fund Management (CFM) bought 9,098 Viking Therapeutics shares in Q1 2026, an estimated $292K.
  • Viking Therapeutics made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #1809 holding.
  • Capital Fund Management (CFM) first reported a position in Viking Therapeutics in Q4 2019 and has held it in 8 quarters since.
  • Capital Fund Management (CFM)'s Viking Therapeutics position peaked at $4.92M in Q4 2023.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.